

SUPPLEMENTARY DATA

Supplementary Table 1. Infections for DPP-4 inhibitors (reported as lower level MedDRA term)

	Number of MedDRA terms of infection (n=242)
Upper respiratory tract infections	171 (70.7%)
Upper respiratory tract infection	90 (37.2%)
Nasopharyngitis	37 (15.3%)
Sinusitis	18 (7.4%)
Rhinitis	9 (3.7%)
Pharyngitis	8 (3.3%)
Laryngitis	4 (1.7%)
Acute tracheobronchitis	2 (0.8%)
Influenza	2 (0.8%)
Tracheitis	1 (0.4%)
Lower respiratory tract infections	20 (8.3%)
Pneumonia	12 (5.0%)
Bronchitis	7 (2.9%)
Lower respiratory tract infection	1 (0.4%)
Urinary tract infections	7 (2.9%)
Urinary tract infection	11 (4.5%)
Cystitis	1 (0.4%)
Pyelonephritis	1 (0.4%)
Other infections	51 (21.1%)
Respiratory tract infection NOS	9 (3.7%)
Sepsis	4 (1.7%)
Infection NOS	4 (1.7%)
Fungal infection	3 (1.2%)
Candidiasis	2 (0.8%)
Other infections*	28 (11.6%)

* All reported only once